Plouvier P, Barbotin A-L, Boitrelle F, Dewailly D, Mitchell V, Rigot J-M, Lefebvre-Khalil V, Robin G
Service de Gynécologie Endocrinienne et Médecine de la Reproduction, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire, Lille, France.
Service de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire, Lille.
Andrology. 2017 Mar;5(2):219-225. doi: 10.1111/andr.12323. Epub 2017 Feb 10.
Patients with very low sperm count through direct sperm examination can exhibit extreme oligozoospermia or cryptozoospermia (after centrifugation). The management of these patients is a real challenge for both clinicians and biologists. In this retrospective and comparative cohort study, we compared the andrological phenotype of patients with extreme alterations of spermatogenesis and assessed whether the origin of spermatozoa (testicular or ejaculate) had any influence on intracytoplasmic sperm injection (ICSI) outcomes. A total of 161 ICSI cycles were performed using ejaculated spermatozoa from 75 patients with extreme oligozoospermia (EOS) or cryptozoospermia (CS) and 150 ICSI cycles using extracted testicular spermatozoa from 74 patients with non-obstructive azoospermia (NOA). Physical, hormonal, ultrasound assessments, and ICSI outcomes were performed in each group. Cryptorchidism was significantly more frequent in the NOA group (60.8% vs. 22.6%, p = 0.001). FSH levels were significantly higher [18.9 IU/L (5.9-27.0) vs. 15.3 IU/L (9.0-46.5), p = 0.001] and the majority of inhibin B levels measured were found mostly undetectable in the NOA group as compared to EOS/CS group (31.1% vs. 10.7%, p = 0.0004). Moreover, we found no significant differences in the respect to the fertilization rates (48.9% and 43.3%, p = 0.43), implantation rates (17.4% and 15.9%, p = 0.77), and percentage of top quality embryo (22.4% and 20.4%, p = 0.73) between the two groups. The clinical pregnancy rates per embryo transferred were comparable in both groups (28.3% and 27.4%, p = 0.89). In this study, we showed for the first time a different andrological phenotype between EOS/CS and NOA groups. Indeed, cryptorchidism was significantly more frequent with more severe endocrine parameters found in the NOA group. These results reflect a more profound alteration in spermatogenesis in NOA patients. However, there was no difference in ICSI outcomes between NOA and EOS/CS groups.
通过直接精液检查发现精子计数极低的患者可能表现为严重少精子症或隐匿精子症(离心后)。对这些患者的治疗对临床医生和生物学家来说都是一项真正的挑战。在这项回顾性比较队列研究中,我们比较了精子发生极度改变患者的男科表型,并评估了精子来源(睾丸或射精)对卵胞浆内单精子注射(ICSI)结果是否有任何影响。共进行了161个ICSI周期,使用了75例严重少精子症(EOS)或隐匿精子症(CS)患者的射出精子,以及150个ICSI周期,使用了74例非梗阻性无精子症(NOA)患者提取的睾丸精子。对每组患者进行了体格、激素、超声评估以及ICSI结果分析。隐睾症在NOA组中明显更常见(60.8%对22.6%,p = 0.001)。NOA组的促卵泡激素(FSH)水平显著更高[18.9 IU/L(5.9 - 27.0)对15.3 IU/L(9.0 - 46.5),p = 0.001],并且与EOS/CS组相比,在NOA组中检测到的大多数抑制素B水平大多无法检测到(31.1%对10.7%,p = 0.0004)。此外,我们发现两组在受精率(48.9%和43.3%,p = 0.43)、着床率(17.4%和15.9%,p = 0.77)以及优质胚胎百分比(22.4%和20.4%,p = 0.73)方面没有显著差异。两组中每个移植胚胎的临床妊娠率相当(28.3%和27.4%,p = 0.89)。在本研究中,我们首次展示了EOS/CS组和NOA组之间不同的男科表型。确实,隐睾症在NOA组中明显更常见,且发现其内分泌参数更严重。这些结果反映了NOA患者精子发生方面更深刻的改变。然而,NOA组和EOS/CS组在ICSI结果方面没有差异。